Info

🌱 來自: treatment of chronic myelogenous leukemia (CML)

ponatinib

NOTE: ponatinib the only effective TKI against T315I resistance Mt; alloSCT generally preferred when present

Side effects of tyrosine kinase inhibitor

Backlink

• treatment of chronic myelogenous leukemia (CML)
• T315I
• Small Molecule Pathway Inhibitors
• Side effects of tyrosine kinase inhibitor
• Individualizing Targeted Therapy in Patients With CML With Specific History or Comorbidities
• Hematology - Hematologic Malignancies - Fast Facts NEJM Resident 360